The aim of the study was to evaluate the effect of Utirose™ on its antimicrobial preservation efficiency. The Escherichia coli microbial contamination was analyzed with Utirose™ as a preservative system.
Conclusion: This study showed that Utirose™ has a direct antimicrobial effect. In 24 hours, the Escherichia coli content was reduced by 5 log compared to the initial Escherichia coli microbial contamination.
The bioavailability of Utirose™ has been evaluated on rats. After a single oral administration the urine was analyzed in order to observe the composition.
Conclusions: The study showed that some compounds found in Utirose™ were discovered intact in the urine, demonstrating that Utirose™ can cross intestinal and renal barriers.
Randomized, double blind, placebo controlled clinical study.
A 200 mg supplementation per day with Utirose™ has been clinically proven to:
The in-vivo study evaluated the recurrence of UTIs among women who are particularly susceptible to reoccurring episodes. The results were evaluated after 3 and 6 months with a supplementation with Utirose™.
Conclusion: The frequency of urinary infections reported reduced significantly with Utirose™ compared to 3 months before the study started. After 6 months UTIs were reduced by 89%. The reduction in frequency is all the more significant versus the placebo at 6 months (p<0.01).
In the study, doctors evaluated the efficacy of the supplementation on the basis of the number of urinary tract infections observed during each period.
Conclusion: Doctors considered that the supplementation of Utirose™ was effective in 68% of patients versus only 22% for the placebo.